Objective: Adenomyosis is a common benign gynecological pathology that is frequently associated with endometriosis. Although numerous studies have investigated cardiovascular risk factors in endometriosis, research on these risks in patients with adenomyosis remains scarce. This study aimed to evaluate cardiovascular risk factors in patients diagnosed with adenomyosis. Method: A total of 135 patients (65-study group, 70-control group) were included in the study. Age, known chronic comorbidities, smoking status, blood pressure, body mass index (BMI), and waist-to-hip ratio (WHR) were recorded preoperatively. Blood samples were obtained from patients who received pathology results within the first month after surgery. To evaluate cardiovascular risk factors, tests for total cholesterol, HDL, LDL, triglycerides, and CRP levels were performed. Results: The presence of chronic diseases and smoking status were compared between groups, and no significant differences were found. Additionally, comparisons of smoking, systolic and diastolic blood pressure, height, weight, BMI, WHR, total cholesterol, HDL, LDL, triglycerides, and CRP levels between the groups revealed no significant differences. However, a significant relationship was found between age and adenomyosis, with the mean age of the adenomyosis group being higher than that of the other groups (p < 0.05). Conclusion: No significant relationship was found between adenomyosis and known chronic diseases, smoking (pack-years), systolic and diastolic blood pressure, BMI, WHR, total cholesterol, HDL, LDL, triglycerides, or CRP levels. However, the frequency of adenomyosis increases with age.

Background/Objectives: Preeclampsia is associated with placental, vascular, and endocrine alterations. We compared peripartum maternal androgen-related hormone measures and anogenital distance (AGD) between women with preeclampsia and normotensive controls and assessed whether observed differences persisted after clinical and sampling-related adjustment. Methods: In this prospectively recruited cross-sectional case-control study, 129 women were assessed for eligibility during delivery admission, and 87 women with singleton pregnancies were included: 41 with preeclampsia and 46 normotensive controls. Serum total testosterone, estradiol, androstenedione, dehydroepiandrosterone sulfate, and sex hormone-binding globulin were measured, and the free androgen index (FAI) was calculated. AGD was assessed as anus-to-clitoris distance (AGDac) and anus-to-fourchette distance (AGDaf). Adjusted linear models used heteroscedasticity-consistent robust standard errors; hormone outcomes were log-transformed. Sensitivity analyses excluded at-delivery samples. Results: Women with preeclampsia had higher total testosterone (3.22 vs. 2.31 nmol/L; p = 0.032), higher FAI (0.95% vs. 0.64%; p = 0.007), lower mean AGDac (10.41 vs. 11.35 cm; p = 0.032), and lower mean AGDaf (3.20 vs. 3.72 cm; p = 0.008). In adjusted models, preeclampsia remained associated with higher total testosterone (+78.3%), higher FAI (+99.9%), shorter AGDac (−1.56 cm), and shorter AGDaf (−0.60 cm). After excluding at-delivery samples (n = 69), only the AGDac association remained statistically significant (−1.39 cm; 95% confidence interval, −2.62 to −0.16; p = 0.026). Conclusions: Peripartum endocrine and AGD differences were observed in preeclampsia. After exclusion of at-delivery samples, AGDac remained statistically significant, whereas the endocrine associations and AGDaf did not. These cross-sectional findings do not establish causality or predictive utility and warrant longitudinal confirmation.